Scheusan seeks to buy local drugs for Alvogen

Laurentiu Scheusan, former general manager of Romania-based
Actavis, who has this year taken over the management of the
Romanian office of American-held Alvogen, says his current priority
is to build the company’s portfolio, and that he is interested in
acquiring products and in obtaining the market authorisation.
Alvogen is building a team that will operate on an around 1.8
billion-euro drug market. “Building a product portfolio is our
priority. In order to do that we are seeking the fastest way to get
the products registered, which includes product acquisitions and
market authorisations for the already registered products. Our
second goal is to build a management and a sales team because I
expect we will already have registered products in the second half
of the year,” Scheusan told ZF.